TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28774950
Drug: Lower-dose aerobic
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose aerobic exercise training (33.6 kJ·kg‐1 body weight weekly)
Study: 28774950
Drug: Higher-dose aerobic
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher-dose aerobic exercise training (58.8 kJ·kg‐1 body weight weekly)
Study: 18270716
Drug: Whole-body magnetic
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body magnetic resonance angiography (WBMRA) with 40 ml gadodiamide
Study: 11299593
Drug: Early jejunal
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early jejunal feeding combined with imipenem prophylaxis (Tienam, 2 x 500 mg i.v.)
Study: 11299593
Drug: Conventional parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional parenteral nutrition (Rindex 10, Infusamin S, Intralipid 10%: 30 kcal/kg)
Study: 6391131
Drug: Intravenous verapamil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous verapamil, 5 to 10 mg/hour for 2 days
Study: 6391131
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (25 patients with no specific treatment)
Study: 27090574
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin administration
Study: 27090574
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of heparin
Study: 24370033
Drug: Bisphosphonates combined
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonates combined with traditional chemotherapy (B group)
Study: 15964703
Drug: Nicopass 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicopass 1.5 mg nicotine lozenge
Study: 12505931
Drug: Routine oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oxygen administration with 30% oxygen, balance nitrogen (Group A)
Study: 9371353
Drug: Zidovudine 100
Normalized name: zidovudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine 100 mg oral capsule, administered five times a day for 3 days and a single dose on day 4
Study: 9371353
Drug: Zidovudine 100
Normalized name: zidovudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine 100 mg oral capsule with megestrol acetate 800 mg (40 mg/ml aqueous suspension) administered for 13 days
Study: 3161531
Drug: Ketanserin (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (20-40 mg twice daily)
Study: 31403367
Drug: 10% topical
Normalized name: BP 10% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% topical minoxidil
Study: 20012563
Drug: Immunomodulatory therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulatory therapy with thalidomide or lenalidomide combined with dexamethasone
Study: 20012563
Drug: Immunomodulatory therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulatory therapy with thalidomide or lenalidomide combined with bortezomib
Study: 20012563
Drug: Immunomodulatory therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulatory therapy with thalidomide or lenalidomide combined with akt inhibitors
Study: 20012563
Drug: Immunomodulatory therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulatory therapy with thalidomide or lenalidomide combined with HDAC inhibitors
Study: 20012563
Drug: Immunomodulatory therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulatory therapy with thalidomide or lenalidomide combined with monoclonal antibodies
Study: 18975051
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of iopamidol 300 at an injection rate of 3.0 ml/s
Study: 18975051
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of iopamidol 300 at an injection rate of 3.7 ml/s
Study: 18975051
Drug: 80 ml
Normalized name: urinary bag 480 mL MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 ml of iopamidol 370 at an injection rate of 3.0 ml/s
Study: 16637481
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group IN (MOD inlay preparation)
Study: 11304641
Drug: CODAS verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: CODAS verapamil PM 200 mg dosed nightly
Study: 11304641
Drug: Immediate‐acting verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate‐acting verapamil 80 mg dosed three times daily
Study: 11304641
Drug: Both medications
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both medications tested
Study: 8630717
Drug: Acrivastine 8
Normalized name: acrivastine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acrivastine 8 mg plus pseudoephedrine HCl 60 mg
Study: 1450287
Drug: Physostigmine (anticholinesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (anticholinesterase inhibitor)
Study: 2858839
Drug: Regular interval
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular interval (RI) group - buprenorphine 0.3 mg IV before anaesthesia, followed by sublingual buprenorphine 0.4 mg 6 hourly postoperatively
Study: 2858839
Drug: On demand
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On demand (OD) group - meperidine 1 mg/kg on demand in recovery room, followed by ketobemidone 5 mg subcutaneously on demand
Study: 31340846
Drug: Active abdominal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active abdominal functional electrical stimulation (FES) for 30 minutes, twice per day, 5 days per week until ICU discharge.
Study: 31340846
Drug: Sham (control)
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham (control) abdominal functional electrical stimulation for 30 minutes, twice per day, 5 days per week until ICU discharge.
Study: 20225533
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with subcutaneous injections of Dp and Df extracts
Study: 18627266
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg annual zoledronate (n = 17)
Study: 15040821
Drug: Low-magnitude, high-frequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-magnitude, high-frequency mechanical stimuli (vibration) - 2.0 m/s2 peak to peak, 30 Hz, two 10-minute treatments/day
Study: 11048608
Drug: Third-generation aromatase
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-generation aromatase inhibitors
Study: 11562748
Drug: Anti-HER2 monoclonal
Normalized name: Recombinant humanized IgG1 anti-HER2 monoclonal antibody conjugated to Duostatin-5
DrugBank: A166 (DB17413)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-HER2 monoclonal antibody Trastuzumab
Study: 2897172
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline, 0.03 ml/kg)
Study: 12684609
Drug: Risperidone (4-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (4-8 mg/day)
Study: 24021217
Drug: Escitalopram (SSRI)
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram (SSRI) with low-transcription 1A receptor genotype
Study: 24021217
Drug: Escitalopram (SSRI)
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram (SSRI) with high-expressing genotypes in serotonin transporter, 1A, or 2A receptors
Study: 17692137
Drug: Fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented milk with probiotics and inulin (4 g)
Study: 15958324
Drug: Complex Hongyibuxue
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex Hongyibuxue oral solution
Study: 9698951
Drug: Ketorolac 1
Normalized name: ketorolac 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 1 mg.kg-1 i.v. preoperative
Study: 9698951
Drug: Ketorolac 1
Normalized name: ketorolac 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 1 mg.kg-1 i.v. postoperative
Study: 2240674
Drug: 400-micrograms clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400-micrograms clonidine bolus followed by 10 micrograms/h clonidine infusion
Study: 2240674
Drug: 800-micrograms clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 800-micrograms clonidine bolus followed by 20 micrograms/h clonidine infusion
Study: 2240674
Drug: Saline bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline bolus followed by 24-h saline infusion
Study: 2240674
Drug: 20 micrograms/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms/h clonidine infusion
Study: 25841300
Drug: Saxagliptin-metformin
Normalized name: metformin / saxagliptin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin-metformin
Study: 25841300
Drug: Acarbose-metformin
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose-metformin
Study: 21354682
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate (1 tablet containing 1,000 mg of elemental lanthanum)
Study: 21354682
Drug: Sevelamer carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer carbonate (three 800-mg tablets)
Study: 17069768
Drug: Prazosin (13.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (13.3 +/- 3 mg/day)
Study: 16551154
Drug: Cognitive‐behavioral group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral group therapy
Study: 15279523
Drug: Exposure group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure group therapy without explicit cognitive interventions
Study: 9506731
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg prednisolone daily for 3.7 +/- 0.6 months (range, 1-6)
Study: 30580089
Drug: Supervised Pelvic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised Pelvic Floor Muscle Training (PFMT) and biofeedback plus conservative treatment
Study: 30580089
Drug: Attention-control massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attention-control massage treatment plus conservative treatment
Study: 28735217
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses (5mg and 10mg zopiclone)
Study: 21804212
Drug: Silodosin 2
Normalized name: Silodosin
DrugBank: Silodosin (DB06207)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Silodosin 2 mg
Study: 21571345
Drug: Silodosin 4
Normalized name: silodosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin 4 mg
Study: 21804212
Drug: Silodosin 12
Normalized name: Silodosin
DrugBank: Silodosin (DB06207)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Silodosin 12 mg
Study: 21804212
Drug: Silodosin 4
Normalized name: silodosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin 4 mg (multiple dosing)
Study: 16404360
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC 7) followed by docetaxel 100 mg/m² (arm A)
Study: 16404360
Drug: Docetaxel 60
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 60 mg/m² with irinotecan 200 mg/m² (arm B)
Study: 8034840
Drug: Adrenalized solutions
Normalized name: adrenal cortex extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenalized solutions (with epinephrine 1:200,000)
Study: 19564260
Drug: Nonstudy antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonstudy antibiotics
Study: 12776814
Drug: Antiprex (Elpen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiprex (Elpen, Greece) 20 mg
Study: 12776814
Drug: Renitec (Vianex,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renitec (Vianex, Greece) 20 mg
Study: 8831919
Drug: Ciprofibrate, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofibrate, 100 mg/day once daily
Study: 8831919
Drug: Gemfibrozil, 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil, 1200 mg/day twice daily
Study: 1314922
Drug: Plain cardioplegic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain cardioplegic solution
Study: 3893007
Drug: sc human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sc human growth hormone
Study: 3893007
Drug: im growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: im growth hormone therapy
Study: 9675959
Drug: Carvedilol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (50 mg/day)
Study: 31343094
Drug: ETC-206, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETC-206, an oral Mnk 1/2 kinase inhibitor
Study: 30665869
Drug: Ramucirumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab (8 mg/kg IV every 2 weeks)
Study: 26048277
Drug: Ramucirumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab (8 mg/kg IV every 2 weeks) + Paclitaxel (80 mg/m² on days 1, 8, and 15 of 28-day cycles)
Study: 16713143
Drug: Conventional-dose HT
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose HT (2 mg 17beta-estradiol + 1 mg NETA)
Study: 16713143
Drug: Low-dose HT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose HT (1 mg 17beta-estradiol + 0.5 mg NETA)
Study: 11282903
Drug: Intracoronary insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary insulin infusion
Study: 9272389
Drug: Lansoprazole plus
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole plus amoxicillin
Study: 3060612
Drug: Ketoprofen (200-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (200-300 mg/day)
Study: 3060612
Drug: Indomethacin (100-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100-150 mg/day)
Study: 3060612
Drug: Ketoprofen (200-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (200-300 mg/day) and Indomethacin (100-150 mg/day)
Study: 27922028
Drug: Lubiprostone (48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone (48 mcg per day)
Study: 21218307
Drug: Consistent methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consistent methadone treatment
Study: 21218307
Drug: Skills for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skills for avoiding and refusing drugs, coping with stress, and maintaining recovery-supportive friendships
Study: 17027436
Drug: Oily fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oily fish (4.5 g eicosapentaenoic acid + docosahexanoic acid)
Study: 17027436
Drug: White fish
Normalized name: WHITE FISH
DrugBank: White fish (DB10627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White fish (0.7 g eicosapentaenoic acid + docosahexanoic acid)
Study: 12717871
Drug: Asthma medication
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asthma medication including inhaled salbutamol 200 microg four times a day and budesonide 400 microg twice a day for 6 weeks
Study: 12717871
Drug: Asthma medication
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asthma medication plus antireflux therapy including oral omeprazole 20 mg once a day and domperidone 10 mg three times a day for 6 weeks
Study: 11157692
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) 1 g/kg on days 1 and 2 and 0.4 g/kg on days 14 and 28
Study: 7903211
Drug: Tertatolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tertatolol (5 mg)
Study: 7903211
Drug: Tertatolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tertatolol (5 mg) and Prazosin (1 mg)
Study: 3425213
Drug: Lorazepam 1
Normalized name: lorazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 1 mg FDDF
Study: 3425213
Drug: Lorazepam 2
Normalized name: lorazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 2 mg FDDF
Study: 21255627
Drug: 1% whey
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% whey protein beverage (5 g, 93 kJ)
Study: 21255627
Drug: 2% whey
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% whey protein beverage (10 g, 178 kJ)
Study: 21255627
Drug: 4% whey
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% whey protein beverage (20 g, 348 kJ)
Study: 19505883
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy plus CRT
Study: 9427903
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin A therapy
Study: 8487050
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy and carmustine (BCNU)
Study: 3301079
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg intravenous dose of captopril
Study: 3301079
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg intravenous dose of captopril
Study: 3301079
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg intravenous dose of captopril
Study: 31950979
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C (1.5 g every 6 hours), hydrocortisone (50 mg every 6 hours), and thiamine (200 mg every 12 hours)
Study: 31950979
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone (50 mg every 6 hours) alone
Study: 27832548
Drug: 6.4% maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.4% maltodextrin solution with sweetener (CHO)
Study: 24374357
Drug: Phonophoresis (PP)
Normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonophoresis (PP) with capsaicin treatment and exercises
Study: 19020160
Drug: Bupivacaine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine infusion above the fascia (group AF, n = 29)
Study: 19020160
Drug: Bupivacaine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine infusion below the fascia (group BF, n = 31)
Study: 15897784
Drug: Carvedilol therapy
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol therapy (group 1)
Study: 21094838
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (group 2)
Study: 1280862
Drug: Heparin (5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (5,000 IU i.v.)
Study: 6703348
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (all doses)
Study: 24503279
Drug: Methylphenidate as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate as add-on therapy to mirtazapine
Study: 24503279
Drug: Placebo as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as add-on therapy to mirtazapine
Study: 19188136
Drug: Cetuximab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (400 mg/m² day 1 followed by weekly 250 mg/m²) + paclitaxel (225 mg/m²)/carboplatin (AUC6) day 1 every 3 weeks
Study: 19188136
Drug: Cetuximab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (400 mg/m² day 1 followed by weekly 250 mg/m²) + paclitaxel (100 mg/m²) days 1, 8, and 15 every 3 weeks and carboplatin (AUC6) day 1 every 4 weeks
Study: 15970000
Drug: Luteal FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteal FSH suppression by physiological oestradiol doses
Study: 15970000
Drug: Luteal oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteal oestradiol administration
Study: 15970000
Drug: Premenstrual GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premenstrual GnRH antagonist administration
Study: 12532716
Drug: Concomitant radio-chemotherapy
Normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant radio-chemotherapy
Study: 9881328
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg of conjugated equine estrogen (CEE) daily (group 1)
Study: 9881328
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg of conjugated equine estrogen (CEE) daily (group 2)
Study: 3396459
Drug: Auxiliary prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auxiliary prescription labels (study sticker)
Study: 3396459
Drug: No auxiliary
Approvals — FDA: no, EMA: no, PMDA: no
Description: No auxiliary prescription labels (control group)
Study: 31758556
Drug: TAU +
Normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU + 7 weekly 90-minute sessions of AF-EMDR (N = 55)
Study: 29567761
Drug: Subcutaneous IL-1
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous IL-1 receptor antagonist (IL-1Ra) 100 mg administered twice daily for 3 days
Study: 21923854
Drug: Modified constraint‐induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified constraint‐induced therapy (mitt on the unaffected hand for 2 hours each day for 8 weeks)
Study: 21923854
Drug: Intensive occupational
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive occupational therapy (8 weeks)
Study: 19144261
Drug: Olopatadine HCl
Normalized name: olopatadine HCl
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olopatadine HCl nasal spray 0.6% (OLO)
Study: 10976548
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (21 mg patch)
Study: 1404796
Drug: Magnesium chloride,
Normalized name: Magnesium Chloride, Injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium chloride, 2 g intravenous infusion
Study: 4003371
Drug: Cefoxitin antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin antibiotic prophylaxis